Literature DB >> 16716206

Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population.

N Aoyama1, N Takahashi, S Saito, N Maeno, R Ishihara, X Ji, H Miura, M Ikeda, T Suzuki, T Kitajima, Y Yamanouchi, Y Kinoshita, K Yoshida, N Iwata, T Inada, N Ozaki.   

Abstract

Several lines of evidence suggest that metabolic changes in the kynurenic acid (KYNA) pathway are related to the etiology of schizophrenia. The inhibitor of kynurenine 3-monooxygenase (KMO) is known to increase KYNA levels, and the KMO gene is located in the chromosome region associated with schizophrenia, 1q42-q44. Single-marker and haplotype analyses for 6-tag single nucleotide polymorphisms (SNPs) of KMO were performed (cases = 465, controls = 440). Significant association of rs2275163 with schizophrenia was observed by single-marker comparisons (P = 0.032) and haplotype analysis including this SNP (P = 0.0049). Significant association of rs2275163 and haplotype was not replicated using a second, independent set of samples (cases = 480, controls = 448) (P = 0.706 and P = 0.689, respectively). These results suggest that the KMO is unlikely to be related to the development of schizophrenia in Japanese.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716206     DOI: 10.1111/j.1601-183X.2006.00231.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  22 in total

1.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

2.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.

Authors:  Ikwunga Wonodi; O Colin Stine; Korrapati V Sathyasaikumar; Rosalinda C Roberts; Braxton D Mitchell; L Elliot Hong; Yasushi Kajii; Gunvant K Thaker; Robert Schwarcz
Journal:  Arch Gen Psychiatry       Date:  2011-07

Review 3.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

4.  The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia.

Authors:  Martina Ulivieri; Joanna Monika Wierońska; Luana Lionetto; Katiuscia Martinello; Paulina Cieslik; Agnieszka Chocyk; Martina Curto; Luisa Di Menna; Luisa Iacovelli; Anna Traficante; Francesca Liberatore; Giada Mascio; Nico Antenucci; Giuseppe Giannino; Matteo Vergassola; Anna Pittaluga; Valeria Bruno; Giuseppe Battaglia; Sergio Fucile; Maurizio Simmaco; Ferdinando Nicoletti; Andrzej Pilc; Francesco Fazio
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 5.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

Authors:  Ikwunga Wonodi; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-02-10       Impact factor: 9.306

6.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

7.  Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.

Authors:  Maria Holtze; Peter Saetre; Göran Engberg; Lilly Schwieler; Thomas Werge; Ole A Andreassen; Håkan Hall; Lars Terenius; Ingrid Agartz; Erik G Jönsson; Martin Schalling; Sophie Erhardt
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

8.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

Review 9.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

10.  Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats.

Authors:  Ana Pocivavsek; Marian A R Thomas; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2014-03-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.